

CASE ON/4-32680A

<b>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</b>	
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
DEFFEZ ET AL.

Art Unit: 1615

INTERNATIONAL APPLICATION NO: PCT/EP03/11351

FILED: 14 OCTOBER 2003

U.S. APPLICATION NO: 10/530,856

35 USC §371 DATE: 3 JANUARY 2006

FOR: DEFERASIROX DISPERSIBLE TABLETS

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Supplemental Information Disclosure Statement filed December 4, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
Oona A. Manzari  
Attorney for Applicants  
Reg. No. 48,152

Date: July 7, 2008